ClearPath partners with leading biopharmaceutical companies to expand early product pipeline opportunities and minimize financial impact:
› Team members have formed and managed multiple product development companies (DevCos) over 30 years
› Advanced over 20 DevCo programs through clinical POC
› Established relationships with institutional investors
› Leverages the development execution capabilities of RRD International
› This model includes business consulting services which includes researching and performing diligence on businesses and commercial ventures; and consulting services in the field of life sciences.
ClearPath’s model enables:
› Highly capital efficient model for development of early stage assets
› Accelerated development for both existing company assets and external assets under consideration for in-licensing
› De-risking of development projects with tailored financing structures and options to acquire POC-stage assets
Strategic Partnership with Astellas
ClearPath currently has a strategic partnership with Astellas Pharma Inc. to develop infectious disease vaccines. The partnership was established to support Astellas’ goal of building a global vaccine franchise.
Meet the Team
ClearPath Oncology is forming a portfolio of Oncology/Immunology, development-stage assets, by the in-licensing of targeted compounds through pre-defined, Proof-of Concept (PoC) milestones. Attaining PoC triggers a pre-negotiated sale of the asset to a partnering, pharmaceutical company.
Meet the Team